ライフサイエンスコーパス: iduronate

1 ulfation of glucosamine residues rather than iduronate 2-O-sulfation being important for bioactivity.

2 A signal peptide sequence with that of human iduronate 2-sulfatase (IDS) achieved higher transgene ex

3 two distinct TfR-targeted platforms fused to iduronate 2-sulfatase (IDS), a lysosomal enzyme deficien

4 lfate storage, consistent with inhibition of iduronate 2-sulfatase.

5 that heparan sulfate and heparin can inhibit iduronate 2-sulfatase.

6 ed a tandem mass spectrometry based assay of iduronate-2-sulfatase (IdS) activity for the neonatal de

7 om alpha-L-iduronidase (IDUA) deficiency and iduronate-2-sulfatase (IDS) deficiency, respectively.

8 er due to a mutation in the lysosomal enzyme iduronate-2-sulfatase (IDS) gene.

9 I subject had a transient increase in plasma iduronate-2-sulfatase approaching normal levels and one

10 caused by mutations in the IDS gene encoding iduronate-2-sulfatase, a crucial enzyme in the lysosomal

11 strates for the enzymes alpha-l-iduronidase, iduronate-2-sulfatase, and N-acetylgalactosamine-4-sulfa

12 the higher-order structures in idursulfase (iduronate-2-sulfatase, I2S) has been accomplished throug

13 Leukocyte L-O-(alpha-iduronate-2-sulfate)-(1->4)-D-O-2,5-anhydro[1-3H]mannito

14 etic substrate (IdS-S) consisting of alpha-L-iduronate-2-sulfate, which is glycosidically conjugated

15 -linked lysosomal storage disorder caused by iduronate-2-sulphatase (IDS) deficiency.

16 -ray structures of a novel distorted (4)C(1) iduronate 4,6-lactone.

17 (DS, formerly dermatan sulphate), contains L-iduronate, an elastic sugar unit.

18 es of phi (phi) and psi (psi) angles between iduronate and glucosamine rings.

19 teresting interplay between requirements for iduronate and sulfate density that may reflect in part a

20 ulfation of hexosamines and 2-O-sulfation of iduronates are not absolute requirements for glycosamino

21 iduronate diacetate C-4 acceptor, and also L-iduronate C-4 acceptor thioglycosides.

22 ts as a conformational switch to superdisarm iduronate components, reversible by lactone ring opening

23 e binding site in the protein to accommodate iduronate-containing sequences of variable sulfation pat

24 For biglycan and decorin, iduronate content was linearly correlated with age (incr

25 te enables short, scalable syntheses of an L-iduronate diacetate C-4 acceptor, and also L-iduronate C

26 adopt (1)C(4) conformations in solution, the iduronate ester adopts the (4)C(1) conformation in solid

27 fated trisaccharide comprised of an internal iduronate flanked by monosulfated hexosamine residues an

28 ulfation patterns, with only the presence of iduronate in common.

29 conformationally locked bicyclic 1,6-anhydro iduronate lactone along with an X-ray structures of a no

30 X-ray structures are reported for a [2.2.2] iduronate lactone and examples of both methyl L-idopyran

31 step routes to bicyclic [3.2.1] or [2.2.2] L-iduronate lactones.

32 nase I-like, cleaving at hexosamine-sulfated iduronate linkages, whereas the other is presumably hepa

33 X-ray and NMR data of the 1,2-diacetyl iduronate methyl ester and the analogous iduronamide sho

34 digests of heparin that contains a Delta-2S-iduronate on the non-reducing end does not initiate the

35 rbation of the conformational equilibrium of iduronate residue G through replacement of the nonessent

36 cludes the carboxylate group at the adjacent iduronate residue.

37 binding sequences separated by a nonsulfated iduronate residue.

38 The presence of 2-O-sulfation on the iduronate residues does not appear to be inhibitory.

39 A sequence comprising unsulfated iduronate residues in combination with 4-O-sulfated N-ac

40 L-iduronate residues in shape module decoran PGs are sugge

41 ppeared to contain at least two 2-O-sulfated iduronate residues, but no 6-O-sulfate groups.

42 oration of conformational variability of the iduronate residues.

43 lfate fine structure, where highly sulfated, iduronate-rich domains alternate with N-acetylated domai

44 rs endows these chains with highly sulfated, iduronate-rich regions, which are major determinants of

45 es either pure anomer of the novel [2.2.2] l-iduronate thioglycoside lactones.

46 from 1 to a new type of highly disarmed O-4 iduronate thioglycoside, which is an effective acceptor

47 arin, and (iii) that removal of the Delta-2S-iduronate to expose the fully sulfated trisaccharide (Gl

48 e of glucosamine, but not the 2-O-sulfate of iduronate within heparin is required for 3Q binding, ind